CellSystems

Dear Customer,

you have noticed that CellSystems has changed its corporate design in January 2012.

This new CD reflects a realignment of our future business strategy. A major part of this strategy is the strengthening and expanding of our core competence within the business segment in vitro models.

To underline this strategic decision the well established in vitro model “EST1000”, an ECVAM validated reconstructed epidermis for toxicology applications, is going  to be changed into “epiCS®”, the new family name of the technology.

epiCS, a fusion of “epithelial” and “CellSystems” marks the starting point for a growing product family leading to diversification of applications and synergistic effects. However, the name change does not imply any technical changes to the product, nor to any regulatory acceptance.

Every accomplishment starts with a decision to try…  Test us!